Categories: Clinical TrialNews

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 9:30 a.m. ET in New York, NY.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

William Gramig
Stern Investor Relations, Inc.
william.gramig@sternir.com

Staff

Recent Posts

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),…

3 hours ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4…

5 hours ago

Healthcare Analytical Testing Services Market worth $12.48 billion by 2030 with 10.8% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 25, 2025 /PRNewswire/ -- The global Healthcare Analytical Testing Services Market,…

6 hours ago

Dynamic Infrastructure Partners with The Advocacy Partners to Accelerate AI-Driven Bridge Maintenance Across Florida

TALLAHASSEE, Fla., July 25, 2025 /PRNewswire/ -- Dynamic Infrastructure (diglobal.tech), the leading provider of AI-powered…

6 hours ago

Weekly Recap: 12 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's…

6 hours ago

Red Light Holland Selects Arch Public for Bitcoin Purchases on Recommendation from Advisor Scott Melker

Toronto, Ontario--(Newsfile Corp. - July 25, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE:…

9 hours ago